Literature DB >> 17404789

PET-CT vs. CT alone in ovarian cancer recurrence.

Sunit Sebastian1, Susanna I Lee, Neil S Horowitz, James A Scott, Alan J Fischman, Joseph F Simeone, Arlan F Fuller, Peter F Hahn.   

Abstract

BACKGROUND: To compare fusion, positron emission tomography-computed tomography (PET-CT) with CT alone in detecting ovarian carcinoma recurrence.
METHODS: Fifty-one consecutive patients underwent 53 restaging PET-CT scans with a concurrent diagnostic quality CT scan. Two body imaging radiologists independently assessed the CT's; each then teamed with a nuclear medicine specialist to review the PET-CT's. Two teams conferred for consensus on the presence of disease in the chest, abdomen, and body overall with CT alone and with PET-CT, using a six-point reader confidence metric to determine accuracy and receiver operating characteristic (ROC) curves. Reader agreement was compared using kappa. Recurrence was determined by two gynecologic oncologists reviewing clinical records from time of presentation to at least 13 months (mean 22.7) after imaging.
RESULTS: Recurrence was based on histopathology in 17% (9/53). Seventy-two percent (38/53) cases had recurrence, with two cases showing isolated chest recurrence. PET-CT accuracy exceeded CT for body 92% (49/53) vs. 83% (44/53), chest 96% (51/53) vs. 89% (47/53), and abdomen 91% (48/53) vs. 79% (42/53). ROC curves for PET-CT dominated that for CT alone; this difference was statistically significant for abdomen and for body overall (P < 0.01). Interobserver agreement was better for PET-CT than for CT alone.
CONCLUSIONS: PET-CT demonstrates greater accuracy and less interobserver variability than CT alone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17404789     DOI: 10.1007/s00261-007-9218-0

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  15 in total

Review 1.  FDG-PET in gynaecological cancers: recent observations.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11       Impact factor: 9.236

Review 2.  Imaging ovarian cancer and peritoneal metastases--current and emerging techniques.

Authors:  Stavroula Kyriazi; Stan B Kaye; Nandita M deSouza
Journal:  Nat Rev Clin Oncol       Date:  2010-04-13       Impact factor: 66.675

3.  Benefits of fluorine-18 fludeoxyglucose positron emission tomography in secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer.

Authors:  P Peng; Z H Zhu; Z J Zhong; K Zheng; J X Yang; D Y Cao; K Shen
Journal:  Br J Radiol       Date:  2015-05-20       Impact factor: 3.039

4.  Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?

Authors:  Ahmet Bilici; Bala Basak Oven Ustaalioglu; Mesut Seker; Nesrin Canpolat; Bulent Tekinsoy; Taflan Salepci; Mahmut Gumus
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

5.  The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review.

Authors:  N B Rettenmaier; C R Rettenmaier; T Wojciechowski; L N Abaid; J V Brown; J P Micha; B H Goldstein
Journal:  Br J Cancer       Date:  2010-11-02       Impact factor: 7.640

6.  Comparison of 18F-FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study.

Authors:  Lino M Sawicki; Julian Kirchner; Johannes Grueneisen; Verena Ruhlmann; Bahriye Aktas; Benedikt M Schaarschmidt; Michael Forsting; Ken Herrmann; Gerald Antoch; Lale Umutlu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-21       Impact factor: 9.236

Review 7.  Present and future role of FDG-PET/CT imaging in the management of gynecologic malignancies.

Authors:  Kazuhiro Kitajima; Yasuhiko Ebina; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2014-04-18       Impact factor: 2.374

8.  Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.

Authors:  Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Domeki; Yasushi Kaji; Ichio Fukasawa; Noriyuki Inaba; Narufumi Suganuma; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-17       Impact factor: 9.236

9.  Impact of FDG PET in optimizing patient selection for cytoreductive surgery in recurrent ovarian cancer.

Authors:  Yasuhiko Ebina; Hidemichi Watari; Masanori Kaneuchi; Mahito Takeda; Masayoshi Hosaka; Masataka Kudo; Hideto Yamada; Noriaki Sakuragi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-13       Impact factor: 9.236

10.  Visualization and quantification of intraperitoneal tumors by in vivo computed tomography using negative contrast enhancement strategy in a mouse model of ovarian cancer.

Authors:  Murtuza Rampurwala; Murali K Ravoori; Wei Wei; Valen E Johnson; Raghunandan Vikram; Vikas Kundra
Journal:  Transl Oncol       Date:  2009-05       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.